Tuesday, October 27, 2026

Strategy Raises STRC Dividend to 12%, Adds $2B Buyback as Bitcoin Premium Turns Negative

Strategy's mNAV — the premium investors pay over its Bitcoin holdings — has dropped below 1, forcing a capital overhaul. The Virginia-based firm hiked its STRC preferred dividend to 12%, authorized a $2 billion buyback, and began selling Bitcoin as global regulators simultaneously tighten scrutiny of stablecoins.

LM Salvado
LM Salvado

July 16, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Strategy Raises STRC Dividend to 12%, Adds $2B Buyback as Bitcoin Premium Turns Negative
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Strategy's market-to-net-asset-value premium has fallen below 1, signaling investors worldwide are pulling back from its leveraged Bitcoin-accumulation model. The US firm is now restructuring its capital framework in response.

Strategy raised its STRC preferred dividend to 12% to retain capital and hold investors as the mNAV slide continued. It also authorized a $2 billion share buyback and launched a monetization program, moving beyond a strategy built solely on accumulating Bitcoin.

Chairman Michael Saylor sold a small amount of Bitcoin as part of the shift — notable given his years-long public refusal to sell. Bitcoin ETFs recorded $4 billion in outflows over the same month, a signal that institutional caution extends well beyond one company.

Regulators outside the US are moving in parallel. The Bank for International Settlements, the Basel-based institution that coordinates central banks globally, cast doubt on stablecoins' status as money in its annual report, arguing they function more like exchange-traded fund shares than a payment instrument.1 The BIS said stablecoins "trade off par" and show "redemption frictions... which we've literally never seen," adding they "don't settle on central bank balance sheets and can't guarantee par across issuers."1

The BIS also warned that dollar-denominated stablecoins are accelerating dollarization in fragile economies, weakening local currencies and undermining capital controls — a concern echoed by central banks in Latin America, Africa and parts of Asia. "You can't enforce border rules on a self-custodied token," the institution said.1

The two developments are linked. Corporate Bitcoin treasuries built on leverage and premium valuation are showing their first real strain, while global regulators signal tighter scrutiny of the stablecoin infrastructure underpinning much of the crypto market worldwide. For Strategy, the overhaul marks a departure from its identity as a pure Bitcoin-accumulation vehicle toward one managing shareholder returns directly through dividends and buybacks — a shift international investors will watch as a bellwether for corporate crypto-treasury strategies globally.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· June 29, 2026
    Saylor's Strategy changes playbook and can now sell its bitcoin

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com